ImmunityBio
(NASDAQ) IBRX
ImmunityBio Financials at a Glance
Market Cap
$8.16B
Revenue (TTM)
$140.98M
Net Income (TTM)
-$854.53M
EPS (TTM)
-$0.85
P/E Ratio
-9.12
Dividend
$0.00
Beta (Volatility)
2.16 (High)
Dividend
$0.00
Beta (Volatility)
2.16 (High)
Price
$8.70
Volume
41,198,290.031
Open
$7.74
Price
$8.70
Volume
41,198,290.031
Open
$7.74
Previous Close
$8.71
Daily Range
$7.67 - $8.85
52-Week Range
$1.95 - $12.43
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
2.16 (High)
Price
$8.70
Volume
41,198,290.031
Open
$7.74
Previous Close
$8.71
Daily Range
$7.67 - $8.85
52-Week Range
$1.95 - $12.43
Estimated Earnings Date
Aug 4, 2026
IBRX News
IBRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout ImmunityBio
Industry
Biotechnology
Sector
Health CareEmployees
691
CEO
Richard Adcock, MBA
Website
www.immunitybio.comHeadquarters
San Diego, CA 92121, US
IBRX Financials
Key Financial Metrics (TTM)
Gross Margin
93.79%
Operating Margin
-185.41%
Net Income Margin
-606.15%
Return on Equity
138.69%
Return on Capital
-67.64%
Return on Assets
-132.15%
Earnings Yield
-10.96%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$8.16B
Shares Outstanding
1.05B
Volume
41.20M
Avg. Volume
14.17M
Financials (TTM)
Gross Profit
$132.23M
Operating Income
-$261.39M
EBITDA
-$726.30M
Operating Cash Flow
-$294.39M
Capital Expenditure
-$4.92M
Free Cash Flow
-$299.31M
Cash & ST Invst.
$380.88M
Total Debt
$1.12B
ImmunityBio Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$44.21M
+167.6%
Gross Profit
$43.97M
+167.1%
Gross Margin
99.46%
N/A
Market Cap
$8.16B
N/A
Market Cap/Employee
$12.16M
N/A
Employees
671
N/A
Net Income
-$632.78M
-388.1%
EBITDA
-$599.95M
-517.2%
Quarterly Fundamentals
Total Cash
$380.88M
+518.4%
Total Debt
$1.12B
+113.7%
Accounts Receivable
$43.27M
+147.9%
Inventory
$547.00K
-93.5%
Long Term Debt
$1.12B
+115.1%
Short Term Debt
$8.56M
+14.8%
Return on Assets
-1.32%
N/A
Return on Invested Capital
-45.17%
N/A
Free Cash Flow
-$77.15M
+11.4%
Operating Cash Flow
-$75.36M
+12.3%